FDA Warning Letter to Genzyme Related to the Allston Manufacturing Facility
Has No Foreseeable Impact on Aldurazyme Sales NOVATO, Calif., March 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the FDA warning letter issued to Genzyme addressing deficiencies related to Genzyme's Allston Landing manufacturing facility duri...Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
CAMBRIDGE, Mass., and NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) and Bioenvision, Inc. (Nasdaq: BIVN ) announced this afternoon that Bioenvision stockholders have voted to approve the acquisition of the company by Genzyme at a reconvened special sharehold...Delaware Court Approves Bioenvision, Genzyme Joint Petition
Special Meeting to be Reconvened on October 22 NEW YORK and CAMBRIDGE, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Bioenvision, Inc. (Nasdaq: BIVN ) and Genzyme Corporation (Nasdaq: GENZ ) announced today that the Court of Chancery of the State of Delaware granted a petition filed ...BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company
...d's top ten tenants are research institutions or A-rated public companies, including Beth Israel Deaconess Medical Center, Children's Hospital Boston, genzyme Corporation, Centocor, Inc. (a Johnson & Johnson subsidiary) and Schering Corporation. Each of BioMed's other top ten tenants publicly announced s...BioMarin Announces Second Quarter 2009 Financial Results
... 22% increase Aldurazyme Net Sales by genzyme $39.2 1% increase Aldurazym...n increase of 1.0 percent compared to net sales by genzyme of $38.7 million for the second quarter of 2008. Net sales of Aldurazyme recorded by genzyme for the six months ended June 30, 2009 were $76.0 ...Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
...zed by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with genzyme Corporation; and Kuvan(R)( )(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division o...Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...e in revenue from the Company's collaboration with genzyme because the three and six months ended June 30, 20... Company received from its strategic alliance with genzyme in 2008 and the gain it recognized on the sale of ...s Highlights "During the last quarter, we and genzyme made great progress regarding mipomersen on two im...Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
...nt and commercialization of its programs, Fovea is working both independently and through collaborations with industrial partners like Dyax, Novartis, genzyme and CombinatoRx, as well as with academic teams, like the Inserm unit U968 (Vision Institute), the Rothschild Ophthalmological Foundation or the Joh...BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
...azyme(R) (laronidase) for MPS I is manufactured by BioMarin and marketed by genzyme Corporation. About MPS IVA Mucopolysaccharidosis IVA (MPS IV...I (MPS I), a product which was developed through a 50/50 joint venture with genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product ...Pain Relief in Just One Visit with Genzyme's Synvisc-One
...opedic Biomaterials 2009 report, the US launch of genzyme Biosurgery's single-injection Synvisc-One will dri...ntly the only approved single-injection treatment, genzyme Biosurgery is positioned to benefit from this shif...thofix), DePuy, Exactech, Ferring Pharmaceuticals, genzyme Biosurgery, Integra LifeSciences, LifeNet Health, ...PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
...nt, evaluation, and marketing. PTC has an exclusive collaboration with genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will market ataluren in the United States and Canada, while genzyme will commercialize the product in other regions of the world. The developm...BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
...zed by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with M...Sepramesh Biosurgical Composite
Description:...s of a PPM mesh that has two distinct sides. One side of the mesh is coated with a layer of sodium hyaluronate and carboxymethylcellulose (similar to genzyme Biosurgery's Seprafilm® Adhesion Barrier). This coated side is bioresorbable, providing a temporary physical barrier that separates the underlying...'Show me the money!' MDA greenlights grants
...ophic lateral sclerosis (ALS), or Lou Gehrig's disease, and spinal muscular atrophy. It also served as the basis for a lifesaving therapy developed by genzyme for a metabolic muscle disease called Pompe disease. At Columbia University, Schon has been awarded a three-year $400,000 grant to continue rese...Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
...h are characterized by progressive weakness and degeneration of the skeletal muscles which control movement. The Muscular Dystrophy Association and genzyme Corporation supported the research. Several forms of Pompe disease affect more than 5,000 people in the U.S. If symptoms appear during infancy, the...Sparta Systems Selected by Genzyme to Optimize Quality Assurance Processes with TrackWise
HOLMDEL, N.J., June 30 /PRNewswire/ -- Sparta Systems, Inc. (Sparta), the maker of TrackWise(R) and the market leader in enterprise quality and compliance management software, today announced that Genzyme, a world-leading biotechnology company, has selected Sparta Systems to enhance its qualit...BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
BioMarin will Continue to Manufacture; Genzyme will Continue to Market and Sell Aldurazyme NOVATO, Calif. and CAMBRIDGE, Mass., Jan. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Genzyme Corporation (Nasdaq: GENZ ) announced toda...BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
WOBURN, Mass., Oct. 25 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Jan van Heek, age 58, as Chairman of the Board of Directors. Mr. van Heek is employed as a...Cytochroma settles lawsuit with Genzyme
Madison, Wis. - Cytochroma, Inc. , a company managed by former employees of Bone Care International, has announced the settling of a lawsuit filed in August 2006 by Genzyme Corp ., the company that acquired Bone Care in 2005. The lawsuit, in which Genzyme claimed that the former Bone Care em...Biotech Hot in July Driven by Positive Drug Data and Acquisitions
...ed in oncology and immunology. It wasn't all good news for biotechs. genzyme shares tumbled more than 6 percent in July following an announcement that t...cient action to correct equipment maintenance and process control problems. genzyme received an FDA warning letter in February citing manufacturing deficiencie...PTC Therapeutics Receives $2.6 Million in Government Grants
...nt, evaluation, and marketing. PTC has an exclusive collaboration with genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will market ataluren in the United States and Canada, while genzyme will commercialize the product in other regions of the world. The developm...Kuvan Receives Priority Review Status From Health Canada
...zed by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of ...BioMarin to Present at the Jefferies Healthcare Conference
...zed by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of ...BioMarin to Present at the Goldman Sachs Healthcare Conference
...zed by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of ...